硼替佐米为主的联合方案治疗多发性骨髓瘤的临床观察

岑海燕, 施文瑜, 徐梦麒, 等. 硼替佐米为主的联合方案治疗多发性骨髓瘤的临床观察[J]. 临床血液学杂志, 2014, 27(1): 61-63. doi: 10.13201/j.issn.1004-2806.2014.01.018
引用本文: 岑海燕, 施文瑜, 徐梦麒, 等. 硼替佐米为主的联合方案治疗多发性骨髓瘤的临床观察[J]. 临床血液学杂志, 2014, 27(1): 61-63. doi: 10.13201/j.issn.1004-2806.2014.01.018
CEN Haiyan, SHI Wenyu, XU Mengqi, et al. Clinical analysis of bortezomib-based chemotherapy in the treatment of newly diagnosed multiple myeloma[J]. J Clin Hematol, 2014, 27(1): 61-63. doi: 10.13201/j.issn.1004-2806.2014.01.018
Citation: CEN Haiyan, SHI Wenyu, XU Mengqi, et al. Clinical analysis of bortezomib-based chemotherapy in the treatment of newly diagnosed multiple myeloma[J]. J Clin Hematol, 2014, 27(1): 61-63. doi: 10.13201/j.issn.1004-2806.2014.01.018

硼替佐米为主的联合方案治疗多发性骨髓瘤的临床观察

详细信息
    通讯作者: 岑海燕,E-mail:cenhaiyan90@126.com
  • 中图分类号: R733.3

Clinical analysis of bortezomib-based chemotherapy in the treatment of newly diagnosed multiple myeloma

More Information
  • 加载中
  • [1]

    HIDESHIMA T,ANDERSON K C.Preclinical studies of novel targeted therapies[J].Hematol Oncol Clin North Am,2007,21:1071-1091.

    [2]

    PALUMBO A,AMBROSINI M T,BENEVOLO G,et al.Bortezomib,melphalan,prednisone,and thalidomide for relapsed multiple myeloma[J].Blood,2007,109:2767-2772.

    [3]

    NIESVIZKY R,RICHARDSON P G,RAJKUMAR S V,et al.The relationship between quality of response and clinical benefit for patients treated on the borlezomib arm of the international,randomized,phase 3 APEX trail in relapsed multiple myeloma[J].Br J Haematol,2008,143:46-53.

    [4]

    张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:232-235.

    [5]

    DURIE B G,HAROUSSEAU J L,MIGUEL J S,et al.International uniform response criteria for multiple myeloma[J].Leukemia,2006,20:1467-1473.

    [6]

    MATEOS M V,HERNANDEZ J M,HERNANDEZ M T,et al.Bortezomib plus melphalan and prednisone in elderly unt reated patients with multiple myeloma:result s of a multicenter phase 1/2 study[J].Blood,2006,108:2165-2172.

    [7]

    PALUMBO A,BRINGHEN S,CARAVITA T,et al.Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma:randomised controlled trial[J].Lancet,2006,367:825-831.

    [8]

    ROSINOL L,ORIOL A,MATEOS M V,et al.A phase II trial of alternating bortezomib and dexamethasone as induction regimen prior autologous stem cell transplantion in younger patients with multiple myeloma:efficacy and clinical implications of tumour reponse kinetics[J].J Clin Oncol,2007,25:4452-4458.

    [9]

    SAN MIGUEL J F,SCHHG R,KHUAGEVA N K,et al.Bortezomib plus melphalanand prednisone for initial treatment of multiple myeloma[J].N Engl J Med,2008,359:906-917.

    [10]

    陈建霖,董丽华,郭小卫,等.硼替佐米联合环磷酰胺和地塞米松治疗多发性骨髓瘤28例临床观察[J].临床血液学杂志,2010,23(3):89-91.

    [11]

    RICHARDSON P G,MITSIADES C,SCHLOSSMAN R,et al.Bortezomib in the front-line treatment of multiple myeloma[J].Expert Rev Anticancer Ther,2008,8:1053-1072.

  • 加载中
计量
  • 文章访问数:  114
  • PDF下载数:  94
  • 施引文献:  0
出版历程
收稿日期:  2013-09-06

目录